Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Cinctive Capital Management LP

Cinctive Capital Management LP boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 295.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,960 shares of the biopharmaceutical company's stock after buying an additional 47,058 shares during the quarter. Cinctive Capital Management LP owned 0.07% of Ultragenyx Pharmaceutical worth $2,649,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Smartleaf Asset Management LLC raised its holdings in Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares in the last quarter. Human Investing LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $42,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $83,000. Nomura Asset Management Co. Ltd. acquired a new position in shares of Ultragenyx Pharmaceutical during the third quarter worth $93,000. Finally, Van ECK Associates Corp increased its holdings in Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 273 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE traded up $1.00 during trading on Tuesday, reaching $33.14. The company had a trading volume of 345,017 shares, compared to its average volume of 793,628. The stock's fifty day moving average price is $40.61 and its 200 day moving average price is $45.75. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $30.46 and a fifty-two week high of $60.37. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of -5.23 and a beta of 0.61.

Remove Ads

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares in the company, valued at approximately $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Howard Horn sold 1,785 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares in the company, valued at $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 124,643 shares of company stock valued at $5,256,268 over the last ninety days. Corporate insiders own 5.80% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on RARE. JPMorgan Chase & Co. upped their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Piper Sandler dropped their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. HC Wainwright restated a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Wells Fargo & Company upped their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a report on Friday, December 20th. Finally, Wedbush restated a "neutral" rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $92.79.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.